Neuraxpharm Group, a European specialty pharmaceutical company focused on the central nervous system (CNS), and mjn-neuro, a Spain-based start-up that designs, manufactures and markets medical devices, announced on Tuesday the signing of a commercialisation agreement for mjn-SERAS, a wearable medical device that aims to predict the risk of having an epileptic seizure.

Neuraxpharm said that with this agreement, it increases its end-to-end offering for patients with epilepsy and enters the beyond-the-pill solutions market. It added that this is a significant step for the company on its path to entering the digital health and wearable medical devices markets. With a growing demand from patients seeking different solutions for unmet needs and for healthcare systems to simplify the go-to-market pathways to make these solutions attainable for everyone, digital health is a critical component of care in CNS with significant potential.

The agreement with mjn-neuro covers all EU member states as well as the UK, Norway, Iceland, Liechtenstein and Switzerland.